
Combined Characterization of microRNA and mRNA Profiles Delineates Early Differentiation Pathways of CD133 + and CD34 + Hematopoietic Stem and Progenitor Cells
Author(s) -
Bissels Ute,
Wild Stefan,
Tomiuk Stefan,
Hafner Markus,
Scheel Hartmut,
Mihailovic Aleksandra,
Choi YeongHoon,
Tuschl Thomas,
Bosio Andreas
Publication year - 2011
Publication title -
stem cells
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.159
H-Index - 229
eISSN - 1549-4918
pISSN - 1066-5099
DOI - 10.1002/stem.627
Subject(s) - biology , progenitor cell , haematopoiesis , cd34 , microrna , stem cell , microbiology and biotechnology , progenitor , messenger rna , genetics , gene
MicroRNAs (miRNAs) have been shown to play an important role in hematopoiesis. To elucidate the role of miRNAs in the early steps of hematopoiesis, we directly compared donor‐matched CD133 + cells with the more differentiated CD34 + CD133 − and CD34 − CD133 − cells from bone marrow on the miRNA and mRNA level. Using quantitative whole genome miRNA microarray and sequencing‐based profiling, we found that between 109 (CD133 + ) and 216 (CD34 − CD133 − ) miRNAs were expressed. Quantification revealed that the 25 highest expressed miRNAs accounted for 73% of the total miRNA pool. miR‐142‐3p was the highest expressed miRNA with up to 2,000 copies per cell in CD34 + CD133 − cells. Eighteen miRNAs were significantly differentially expressed between CD133 + and CD34 + CD133 − cells. We analyzed their biological role by examining the coexpression of miRNAs and its bioinformatically predicted mRNA targets and luciferase‐based reporter assays. We provide the first evidence for a direct regulation of CD133 by miR‐142‐3p as well as tropomyosin 1 and frizzled homolog 5 by miR‐29a. Overexpression of miRNAs in CD133 + cells demonstrated that miR‐142‐3p has a negative influence on the overall colony‐forming ability. In conclusion, the miRNAs expressed differentially between the CD133 + and CD34 + CD133 − cells are involved in inhibition of differentiation, prevention of apoptosis, and cytoskeletal remodeling. These results are highly relevant for stem cell‐based therapies with CD133 + cells and delineate for the first time how the stem cell character of CD133 + cells is defined by the expression of specific miRNAs. S TEM C ELLS 2011;29:847–857